Skip to main content

Table 1 Association between B3GNT6 level and clinicopathological factors from dataset GSE39582

From: Downregulation of B3GNT6 is a predictor of poor outcomes in patients with colorectal cancer

Variables

Testing cohort (n=443)

Validating cohort (n=123)

High (n=170)

Low (n=273)

p value

High (n=49)

Low (n=74)

p value

Age

 ≥65

101

166

0.7351

35

52

0.8901

 <65

69

106

 

14

22

 

 Unavailable

0

1

 

0

0

 

Gender

 Male

90

147

0.8527

32

41

0.2738

 Female

80

126

 

17

33

 

Stage

 I-II

84

137

0.9321

28

48

0.3882

 III-IV

82

136

 

21

26

 

T stage

 T1-T2

21

26

0.3574

2

11

0.0625

 T3-T4

145

239

 

43

59

 

 Unavailable

4

8

 

4

4

 

Lymph node metastasis

 Absent

88

142

0.8803

26

46

0.3906

 Present

76

119

 

19

24

 

 Unavailable

6

12

 

4

4

 

Distant metastasis

 Absent

150

226

0.1474

40

66

0.3078

 Present

16

38

 

4

3

 

 Unavailable

4

9

 

5

5

 

Tumor Location

 Distal

96

171

0.1971

27

48

0.2772

 Proximal

74

102

 

22

26

 

MMR

 dMMR

18

43

0.1222

5

9

0.6202

 pMMR

139

209

 

41

55

 

 Unavailable

13

21

 

3

10

 

CIMP status

 −

111

195

0.1855

38

61

0.4994

 +

33

41

 

8

9

 

 Unavailable

26

37

 

3

4

 

CIN status

 negative

41

41

0.0205

17

11

0.0059

 positive

98

176

 

25

55

 

 Unavailable

31

56

 

7

8

 

tp53 mutation

 Mutated

51

84

0.9483

20

35

0.2642

 Wild type

42

68

 

24

27

 

 Unavailable

77

121

 

5

12

 

Kras mutation

 Mutated

84

88

0.0002

20

25

0.496

 Wild type

78

174

 

29

47

 

 Unavailable

8

11

 

0

2

 

Braf mutation

 Mutated

19

25

0.4532

4

3

0.3401

 Wild type

130

218

 

44

69

 

 Unavailable

21

30

 

1

2

 
  1. MMR mismatch repair, dMMR mismatch repair-deficient, pMMR mismatch repair-proficient, CIMP CpG island methylator phenotype, CIN chromosome instability